These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24183125)

  • 1. [Prevalence of hormonal receptors and human epidermal growth factor receptor 2 in Mexican female patients with breast cancer].
    Pérez G; Aranda C; Olivares IM; García JR
    Med Clin (Barc); 2014 Sep; 143(5):231-2. PubMed ID: 24183125
    [No Abstract]   [Full Text] [Related]  

  • 2. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
    Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
    Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative, basal cell type and EGFR positive invasive breast carcinoma in Kuwaiti and British patients.
    Ayad E; Francis I; Peston D; Shousha S
    Breast J; 2009; 15(1):109-11. PubMed ID: 19077133
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
    Li J; Liu X; Tong Z
    Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmenopausal hormone receptor-positive advanced breast cancer.
    Connolly RM; Stearns V
    Oncology (Williston Park); 2013 Jun; 27(6):571-2, 574, 576 passim. PubMed ID: 23909072
    [No Abstract]   [Full Text] [Related]  

  • 6. Triple negative breast cancer: clinicopathological characteristics and treatment strategies.
    Akiyama F; Iwase H
    Breast Cancer; 2009; 16(4):252-3. PubMed ID: 19506994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 8. Triple negative and basal-like breast cancer in East Africa.
    Trinkaus ME; Sayed S; Gakinya SM; Moloo Z; Hanna W; Rahim Y
    Breast J; 2011; 17(4):438-40. PubMed ID: 21752138
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
    Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
    Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 12. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
    Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of decalcification on receptor status in breast cancer.
    Darvishian F; Singh B; Krauter S; Chiriboga L; Gangi MD; Melamed J
    Breast J; 2011; 17(6):689-91. PubMed ID: 21999708
    [No Abstract]   [Full Text] [Related]  

  • 15. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.
    Awadelkarim KD; Arizzi C; Elamin EO; Osman I; Mekki SO; Biunno I; Barberis MC; Mariani-Costantini R
    Breast J; 2013; 19(4):446-7. PubMed ID: 23721068
    [No Abstract]   [Full Text] [Related]  

  • 19. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
    Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
    Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.